High rates of abnormal saccadic eye movements and a shift toward use of second-line disease-modifying therapies lead the notable cohort findings.
The 2018 guideline update includes 30 recommendations — 17 on initiating DMT treatment, 10 on switching DMT agents and three on stopping DMT. The lead author shares key takeaways.
The first generic forms of disease-modifying therapies for MS are here, with more expected soon. Dr. Jeffrey Cohen reflects on how clinicians might best approach them.
The first evidence has emerged that short-term response to MS treatment is related to the underlying inflammatory pathology in MS lesions. An expert puts the findings in context.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Volumetric analysis of brain MRI allows for accurate and prompt rendering of the cortical surface. Here’s how we’re using it in three common neurological diseases.
This image-rich post profiles how we are using machine-learning algorithms to inform detection and delineation of pathological substrates on imaging studies in MS and epilepsy.
The novel therapy cut the rate of brain volume loss by nearly half relative to placebo in the notoriously treatment-refractory progressive form of multiple sclerosis. What’s ahead for ibudilast?
Randomized trials are the research standard, but they can’t address all clinical practice questions. So Cleveland Clinic is deriving real-world evidence from its large patient base to inform multiple sclerosis care.
What’s the best disease-modifying treatment strategy for relapsing-remitting multiple sclerosis: escalation or hitting hard early? A new multicenter study will finally find out.
In multiple sclerosis, blocking the source — rather than the target — of excitotoxic glutamate is a more feasible therapeutic strategy for CNS protection. Neuroscientist Tara DeSilva, PhD, explains why, along with the research implications.